Canadian College of Neuropsychopharmacology

Dr. Francis Wayne Quan Memorial Prize

The Mach-Gaensslen Foundation of Canada and JPN have launched an annual award for the best paper published in the journal, to honour the contributions of psychiatrist and former editor Dr. Francis Wayne Quan to the foundation and the journal.

The Dr. Francis Wayne Quan Memorial Prize has a value of $5000 and will be granted for the first time for a paper published in 2022.

More information can be found here.

CCNP Award Winners

Dr. Bruno Giros is the recipient of the 2022 Canadian College of Neuropsycho-pharmacology (CCNP) Heinz Lehmann Award. Dr. Giros is a Distinguished James B. McGill Professor of Psychiatry at McGill University in Montreal, QC and is also a visiting professor at the Université de Paris. The award is being given this year for basic research. The award, sponsored by Pfizer Canada Inc., consists of a $2,000 honorarium and a suitably engraved plaque. Congratulations to Dr. Giros!

Dr. Gabriella Gobbi is the recipient of the 2022 Canadian College of Neuropsycho-pharmacology (CCNP) Innovations in Neuropsychopharmacology Award. Dr. Gobbi is a Professor in the Department of Psychiatry, McGill University and holds the Canadian Research Chair in Therapeutics for Mental Health (Tier 1). The award is being given this year for basic research. The award, sponsored by Pfizer Canada Inc., consists of a $2,000 honorarium and a suitably engraved plaque. Congratulations to Dr. Gobbi!

Dr. Gary Remington is the recipient of the 2022 CCNP Medal. Dr. Remington is currently a Professor in the Department of Psychiatry, University of Toronto, with a cross appointment in the Department of Psychological Clinical Science. This award, sponsored by the CCNP, consists of a bronze medal engraved with the name of the recipient. Congratulations to Dr. Remington!

Dr. Alexander McGirr is the recipient of the 2022 Canadian College of Neuropsycho-pharmacology (CCNP) Young Investigator Award. Dr. McGirr is an assistant professor and psychiatrist at the University of Calgary. The award is being given this year clinical research. The award, sponsored by Pfizer Canada Inc., consists of a $2,000 honorarium and a suitably engraved plaque. Congratulations to Dr. McGirr!

The Award recipients will be recognized at the annual meeting of the Canadian College of Neuropsychopharmacology which will be held virtually on October 27, 2022.

CCNP 44th Virtual Annual Meeting

October 27, 2022

Keynote Speaker: Dr. Adrian Owen

The Brain and Mind Institute, Western University

Expert in the lasting impact of COVID-19 on the brain

SAVE THE DATE!

Aims and Objectives of the College

The principal function of the Canadian College of Neuropsychopharmacology (CCNP) is to further research and education in neuropsychopharmacology and related fields. To achieve this function, the CCNP values open communication between membership and leadership related to governance of the CCNP, and encourages its members to support integrity, collegiality, and ethics in research. The CCNP is committed to maintaining a level of excellence in the conduct of science, supporting discovery and scientific dialogue within an environment that encourages the free expression and exchange of scientific and educational ideas. The CCNP has a tradition of providing a forum for exchange of scientific information between clinical and basic scientists, which is critical for the advancement and translation of scientific discovery in neuropsychopharmacology.

Mission

The aim of the College shall be:

a) to provide a forum for clinical and basic science researchers to discuss and exchange ideas and experience in neuropsychopharmacology and to promote the development of this science nationally and internationally.

b) to be a liaison body to educational institutions, public, industry and government organizations as well as other related scientific bodies in order to promote quality of research and treatment in this field.

Journal of Psychiatry & Neuroscience

The official journal of the Canadian College of Neuropsychopharmacology

The Journal of Psychiatry & Neuroscience has an impact factor of 6.19 (2020 ISI data) and is ranked at #25 out of 156 Psychiatry journals and #51 out of 273 Neuroscience journals, making it the highest ranking open access journal in biological psychiatry. .
Original research and reviews in basic and clinical science.
As an open access journal our page charges remain very reasonable with no charge for figures and we are now publishing online only for rapid publication of accepted papers. CCNP members are encouraged to consider JPN for submitting their research (https://jpn.ca).

For more information, visit the website of the Canadian Medical Association.

Revue de psychiatrie & de neuroscience

La revue officielle du Collège canadien de neuropsychopharmacologie

Le facteur d'impact de la Revue de psychiatrie et de neuroscience atteint 6,19 (données 2020 de l'ISI), ce qui en fait le journal à accès libre le mieux coté aussi bien dans la catégorie psychiatrie que dans la catégorie neurosciences.
Recherche originale et analyses critiques en sciences
fondamentales et cliniques.
Les articles publiés dans ce journal sont accessibles gratuitement au http://jpn.ca/ et via PubMed Central.

Pour obtenir des informations suplémentaires, visitez le site internet de l'Association Médicale Canadienne.